Necroptosis in cancer: insight from epigenetic, post-transcriptional and post-translational modifications [0.03%]
表观遗传、转录后和翻译后修饰介导的坏死性凋亡在肿瘤中的作用及机制探究
Jinxin Tang,Yan Zhuang,Yibo Zhang et al.
Jinxin Tang et al.
Necroptosis represents a distinct form of programmed cell death that exhibits characteristics of both necrosis and apoptosis. Due to its potential to activate anti-cancer immune responses, utilizing necroptosis to enhance immune activity wi...
Targeting CD276 with Adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide [0.03%]
针对小细胞肺癌的CD276构建adapter-CART细胞提供了一种新的治疗策略并预防CD276依赖性同族杀伤作用
Beate Kristmann,Niels Werchau,Lakshmi Suresh et al.
Beate Kristmann et al.
Background: Survival rates in Small Cell Lung Cancer (SCLC) remain dismal, posing a huge medical need for novel therapies. T-cells, engineered to express chimeric antigen receptors (CAR-T) have demonstrated clinical activ...
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study [0.03%]
伊帕伐单抗和图卡伐单抗（QL1706）联合化疗及贝伐珠单抗治疗EGFR突变型晚期非小细胞肺癌患者厄洛替尼/吉非替尼耐药后患者的Ⅱ期临床研究队列5结果更新
Yaxiong Zhang,Yan Huang,Yunpeng Yang et al.
Yaxiong Zhang et al.
Iparomlimab and tuvonralimab (QL1706), a bifunctional anti-programmed death-1/cytotoxic T-lymphocyte antigen-4 antibody, in combination with bevacizumab and doublet chemotherapy was tolerable and showed preliminary antitumor activity in adv...
Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study [0.03%]
套细胞淋巴瘤伴t(14;19)(q32;q13)的侵袭性CLL的环状RNA特征（ERIC研究）
Eleonora Roncaglia,Enrico Gaffo,Giulia Calabretto et al.
Eleonora Roncaglia et al.
In Chronic Lymphocytic Leukemia (CLL), t(14;19)(q32;q13), leading to the overexpression of BCL3, is found in ∼1% of cases and is associated with an aggressive disease. In this study, leveraging a large CLL patient cohort collected thanks t...
Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML [0.03%]
BTX A51胶囊在血液系统恶性肿瘤(MDS和AML)患者中剂量递增的I期临床研究
Brian J Ball,Wenbin Xiao,Gautam Borthakur et al.
Brian J Ball et al.
Background: BTX A51, a first-in-class oral small molecule inhibitor of casein kinase 1α (CK1α) and cyclin-dependent kinase (CDK) 7 and 9, induces apoptosis of leukemic cells by activating p53 and inhibiting expression o...
Development and validation of a prognostic staging system for primary plasma cell leukemia [0.03%]
原发性浆细胞白血病预后分期系统的开发和验证
Mengru Tian,Gang An,Weijun Fu et al.
Mengru Tian et al.
Background: The existing risk models for multiple myeloma (MM) are suboptimal for the stratification of patients with primary plasma cell leukemia (pPCL), a rare and peculiar MM. In this study, we aimed to develop a stagi...
Multicenter Study
Journal of hematology & oncology. 2025 Jul 15;18(1):72. DOI:10.1186/s13045-025-01723-0 2025
Treatment-related adverse events of antibody drug-conjugates in clinical trials [0.03%]
抗体偶联药物临床试验相关不良反应事件分析
Harold Nathan Tan,Marta Ascanio Morcillo,Juanita Lopez et al.
Harold Nathan Tan et al.
Background: Antibody-drug conjugates (ADCs) aim to enhance the therapeutic index of cytotoxic agents but can cause unexpected toxicities. This study evaluated adverse events (AEs) from phase 1 trials at The Royal Marsden ...
Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance [0.03%]
单细胞和空间组学在解析癌药反应及耐药细胞特征方面的应用
Xiaoxia Cheng,Ting Peng,Tian Chu et al.
Xiaoxia Cheng et al.
Drug resistance poses a significant challenge in cancer therapy, contributing to rapid recurrence, disease progression, and high patient mortality. Despite its critical impact, few reliable predictors for cancer drug response or failure hav...
CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia [0.03%]
靶向CCR9和CD1a的CAR-T细胞治疗T细胞急性淋巴细胞白血病
Néstor Tirado,Klaudyna Fidyt,María José Mansilla et al.
Néstor Tirado et al.
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy characterized by high rates of induction failure and relapse, and effective targeted immunotherapies are lacking. Despite promising clinical progress with genome-edited...
BRD4 acts as a transcriptional repressor of RhoB to inhibit terminal erythropoiesis [0.03%]
BRD4通过抑制RhoB表达负调控红系细胞终末分化
Yijin Chen,Dawei Huo,Ye Meng et al.
Yijin Chen et al.
Background: Terminal erythropoiesis is a complex multistep process involving coordination of gene transcription and dramatic nuclear condensation, which leads to the expulsion of nuclei to generate reticulocytes. However,...